|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538420|
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : April 19, 2012
GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g. after orthopedic surgery) or due to aging (androgenic effect), but without anabolic effects (e.g. effect on testosterone). In the first part of the current study it will be tested whether GLPG0492 given orally to healthy male volunteers increases the protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine.
In the second part of the study, the effect of the compound on the "hormone household" in healthy, postmenopausal women will be assessed.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: GLPG0492 Drug: Placebo||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Assessment of the Muscle Protein Fractional Synthesis Rate Induced by Repeated Administrations of GLPG0492 to Healthy Male Subjects and Assessment of the Safety, Tolerability and Pharmacokinetics of Repeated Administrations of GLPG0492 to Healthy Postmenopausal Women.|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||April 2012|
Experimental: GLPG0492 oral solution
Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
Placebo Comparator: Placebo
Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
Placebo oral solution
- To evaluate the safety and tolerability of GLPG0492 in terms of adverse events, vital signs, ECG and abnormal lab tests in comparison with placebo [ Time Frame: Up to 7 to 10 days after last treatment ]Occurrence of adverse events, vital signs, ECG and abnormal lab tests as a measure of safety and tolerability
- In male volunteers: effect on protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine [ Time Frame: One week ]During a 5-hour infusion of phenylalanine two muscle biopsies will be taken; this procedure is performed before and after one week of treatment with GLPG0492, to determine the effect of the compound.
- To determine the pharmacokinetic profile and metabolism after single and multiple oral doses of GLPG0492 [ Time Frame: Up to 24h hours after last treatment ]The plasma levels of GLPG0492 will be determined as a measure of pharmacokinetics, and the plasma and urine samples will be used for metabolism investigation
- In female volunteers: effects on hormone household. [ Time Frame: up to 7 to 10 days after treatment. ]In female volunteers the effect of two weeks treatment on hormone levels in the blood will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538420
|Study Director:||Florence Namour, MSc||Galapagos SASU|